Immunocore Holdings (IMCR) is One of the Best Small Cap Stocks Ready to Explode in 2026

Immunocore Holdings plc (NASDAQ:IMCR) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 21, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock with a $100 price target. Earlier, on January 6, UBS also initiated Immunocore Holdings plc (NASDAQ:IMCR) with a Buy rating and a $55 price target.

​Analysts at UBS see significant potential upside for the stock because it is currently trading close to the value of its approved drug Kimmtrak. The firm noted that this means that the market has assigned almost no value to two of the company’s upcoming phase 3 trials. UBS believes that these trials could act as catalysts for Immunocore Holdings plc (NASDAQ:IMCR). The firm noted that positive results from the trials have the potential to boost the stock 25%  to 50% and add $300 million to $400 million in annual sales.

​Two upcoming trials for the company include second-line Kimmtrak in metastatic cutaneous melanoma (TEBE-AM trial) with data expected by late 2026 or early 2027, and first-line PRAME, for which data is expected in late 2027 or 2028.

​Immunocore Holdings plc (NASDAQ:IMCR) is a biotechnology company that develops TCR bispecific immunotherapies to treat cancer, infectious diseases, and autoimmune conditions. Using its proprietary ImmTAX technology, the company designs therapies that harness the immune system by either activating it to destroy diseased cells or dampening it to reduce autoimmune responses.

While we acknowledge the potential of IMCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.